SCHEMBL19973716

SCHEMBL19973716

CN1CCC(N)c2cccc(C(=O)Nc3ccc(F)c(F)c3)c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 3/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
MAPK1 P28482 1/20 0.41
HTR1F P30939 1/20 0.40
AKR1C3 P42330 1/20 0.39
FADS1 O60427 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.39
AVPR2 P30518 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974009 0.91 FADS1 (0.52) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL19973418 0.85 TP53 (0.45) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL21189317 0.83 MEN1 (0.41) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL20511812 0.79 TP53 (0.49) MEN1KMT2ATP53CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL20511934 0.78 TP53 (0.48) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL19973435 0.76 FADS1 (0.47) MEN1KMT2ATP53MAPTLMNA
SCHEMBL21175568 0.76 TP53 (0.46) TP53CYP3A4CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL19973483 0.76 TP53 (0.46) MEN1KMT2ATP53CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL19973484 0.76 TP53 (0.46) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL19973641 0.76 TP53 (0.52) MEN1KMT2ATP53CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS MEN1 1933/4885KMT2A 155/4885TP53 166/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS MEN1 1933/4885KMT2A 155/4885TP53 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.